Listen
LIFOG (latanoprost) - Glaucoma and ocular hypertension
Opinions on drugs -
Posted on
Oct 03 2024
Reason for request
Inclusion on list: First listing
Summary of opinion
Favourable opinion for reimbursement in the MA indications: “Reduction of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension.
Reduction of elevated intraocular pressure in paediatric patients with elevated intraocular pressure and paediatric glaucoma.”
No clinical added value compared to the reference medicinal product, XALATAN (latanoprost) 50 µg/ml eye drops solution.
Clinical Benefit
| Substantial |
The Committee considers that the clinical benefit of LIFOG (latanoprost) 50 µg/ml eye drops solution is substantial in the MA indications. |
Clinical Added Value
| no clinical added value |
This medicinal product is a hybrid that does not provide any clinical added value (CAV V) compared to the reference medicinal product, XALATAN 50 μg/ml (latanoprost) eye drops solution. |
Documents
English version
Contact Us
Évaluation des médicaments
